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APC = antigen-presenting cell; CDR = complementarity determining region; CIA = collagen-induced arthritis; CTLA = cytotoxic T lymphocyte-asso-
ciated antigen; DMARD = disease-modifying antirheumatic drug; ICAM = intercellular adhesion molecule; IFN = interferon; IL = interleukin; Ig =
immunoglobulin; LFA = lymphocyte function-associated antigen; MHC = major histocompatibility complex; mAb = monoclonal antibody; RA =
rheumatoid arthritis; TCR = T-cell receptor; Th = T-helper (cell); Treg = regulatory T (cell); TNF = tumor necrosis factor.
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Abstract
T cells, in particular CD4+ T cells, have been implicated in
mediating many aspects of autoimmune inflammation. However,
current evidence suggests that the role played by CD4+ T cells in
the development of rheumatoid inflammation exceeds that of
activated proinflammatory T-helper (Th)1 effector cells that drive
the chronic autoimmune response. Subsets of CD4+ T cells with
regulatory capacity, such as CD25+ regulatory T (Treg) cells and
Th2 cells, have been identified, and recent observations suggest
that in rheumatoid arthritis the function of these regulatory T cells is
severely impaired. Thus, in rheumatoid arthritis, defective regulatory
mechanisms might allow the breakdown of peripheral tolerance,
after which the detrimental Th1-driven immune response evolves
and proceeds to chronic inflammation. Here, we review the
functional abnormalities and the contribution of different T cell
subsets to rheumatoid inflammation.
Introduction
T cells derive from the common lymphoid progenitor in the
bone marrow and migrate via the bloodstream into their primary
lymphoid organ, the thymus, where they undergo a series of
distinct maturation steps. An important role of thymic
maturation is positive selection for those T cells that recognize
self-MHC molecules and negative selection against those T
cells that react to autoantigens [1]. As a consequence of these
dual selection steps, more than 98% of thymocytes die during
maturation. Those T cells that survive thymic selection leave the
thymus and form the peripheral T-cell repertoire (Fig. 1).
Peripheral T cells are characterized by the expression of an
array of distinctive surface receptors [1–3]. The disulfide-
linked heterodimeric T-cell receptor (TCR) confers antigen
specificity to the T cell. The CD3 complex, which consists of
four invariant transmembrane polypeptides (designated γδεε)
mediates signaling and is also necessary for surface
expression of the TCR. The TCR–CD3 complex is associated
with a largely intracytoplasmic homodimer of ζ-chains that are
critical for maximal signaling [4]. Finally, the co-receptors
CD4 and CD8, expressions of which are mutually exclusive
on mature post-thymic T cells, bind to invariant sites of the
MHC class II or I molecules on antigen-presenting cells
(APCs), respectively; they stabilize the MHC–peptide–TCR
complex during T-cell activation, and thus they increase the
sensitivity of a T cell for activation by MHC-presented antigen
by approximately 100-fold [3]. The cytoplasmic domains of
CD4 and CD8 are constitutively associated with the src-
family tyrosine kinase p56lck, which phosphorylates particular
recognition motifs within the CD3 complex (denoted
immunoreceptor tyrosine-based activation motifs), thereby
promoting T-cell activation.
The vast majority of human peripheral blood T cells expresses
TCRs consisting of α and β chains (αβ T cells). αβ T cells
mediate the classical helper or cytotoxic T cell responses.
Extensive somatic DNA recombination of variable and joining
region segments of the α and β TCR genes is responsible for
the structural TCR diversity required for reactivity to the huge
arsenal of potential antigens. TCR diversity is concentrated in
the third hypervariable regions (complementarity determining
region [CDR]3) of the TCR α and β chains, which form the
center of the antigen-binding site of the TCR. As the αβ TCR
does not bind antigen directly, T-cell activation is dependent
on an interaction of the TCR with MHC molecules that
present small peptide fragments that have been generated
from protein antigens. MHC molecules are membrane
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glycoproteins that are encoded by several closely linked,
highly polymorphic genes. Whereas MHC class I molecules
are expressed on virtually all nucleated cells, MHC class II
expression is restricted to professional APCs, such as B
cells, dendritic cells and macrophages, and to activated T
cells in humans. MHC class I molecules bind antigens that
are generated by the particular cells themselves as well as
antigens from intracellular pathogens that reside in the
cytoplasm; they present their antigens to CD8+ T cells. MHC
class II molecules, in contrast, present antigens derived from
ingested proteins, such as extracellular bacteria or damaged
self-tissue, to CD4+ T cells.
A small group of peripheral T cells bears an alternative TCR
that is composed of γ and δ chains (γδ T cells). The function
of the γδ T cells within the human immune system is largely
unknown.  γδ TCRs appear to recognize antigen directly,
similar to immunoglobulins (Igs), but they do not require
presentation by an MHC protein or other molecules and do
not depend on antigen processing. The diversity of the γδ
TCR is limited, suggesting that the ligands for the γδ TCR are
conserved and invariant. γδ T cells have been shown to
recognize self-peptides, such as stress-associated antigens
expressed on epithelial cells, tumor lines, and primary
carcinomas. Recognition of self-peptides and the production
of cytokines early during an immune response indicate that γδ
T cells play a role in the development of an immune response
against self-tissue. Moreover, some recent evidence suggests
a role for γδ T cells in the pathogenesis of rheumatoid arthritis
(RA), because the frequencies of γδ T cells are elevated in
the synovial infiltrates, and rheumatoid synovia with increased
levels of γδ T cells presents with increased tissue
inflammation as compared with RA synovia with few γδ T cells
[5,6]. Despite these indications, however, the function of γδ T
cells, in particular the function of synovial γδ T cells, and their
contribution to rheumatoid inflammation is still as elusive as
the nature of their specific antigen(s).
α αβ β T cells
αβ TCR expressing T cells that survive dual selection in the
thymus can be divided into two subgroups that are
characterized by the expression of either CD4 or CD8. CD4+
T cells primarily function as regulators of other immune cells
either through secreted cytokines or by direct cell–cell
contact. Consequently, CD4+ T cells are denoted T-helper
(Th) cells. CD8+ T cells, on the other hand, are programmed
to become cytotoxic effector cells that kill infected target cells.
CD8+ T cells are therefore named cytotoxic T cells. Both
CD4+ and CD8+ T cells continuously recirculate through the
body from the peripheral blood to secondary lymphoid organs
as they search for the presentation of their specific antigen.
T cells that emerge from the thymus belong to the naïve T cell
pool that consists of T cells that have never encountered their
Figure 1
Schematic representation of T cell development. T cells originate from the common lymphoid progenitor cells in the bone marrow. They migrate as
immature precursor T cells via the bloodstream into the thymus, which they populate as thymocytes. The thymocytes go through a series of
maturation steps including distinct changes in the expression of cell surface receptors, such as the CD3 signaling complex (not shown) and the
coreceptors CD4 and CD8, and the rearrangement of their antigen receptor (T cell receptor, TCR) genes. More than 98% of the thymocytes die
during maturation by apoptosis (†), as they undergo positive selection for their TCR's compatibility with self-major histocompatibility molecules, and
negative selection against those T cells that express TCRs reactive to autoantigenic peptides. In humans, the vast majority of peripheral blood
T cells expresses TCRs consisting of α and β chains (αβ T cells). A small group of peripheral T cells bears an alternative TCR composed of γ and δ
chains (γ/δ T cells). αβ and γδ T cells diverge early in T cell development. Whereas αβ T cells are responsible for the classical helper or cytotoxic
T cell responses, the function of the γδ T cells within the immune system is largely unknown. αβ T cells that survive thymic selection lose expression
of either CD4 or CD8, increase the level of expression of the TCR, and leave the thymus to form the peripheral T cell repertoire.S6
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specific antigen. Naïve T cells are long-lived and have a
restricted function (e.g. CD4+ naïve T cells only produce
IL-2). In humans, naïve T cells are characterized pheno-
typically by the expression of the long isoform of CD45,
namely CD45RA. Naïve T cells are normally limited to
recirculate between the blood and secondary lymphoid
tissues, although in some autoimmune diseases they may also
accumulate in chronically inflamed tissues. Upon proper
activation, naïve T cells proliferate and differentiate into
specialized effector cells. Differentiation of T cells is
characterized by a number of phenotypic and functional
alterations, such as changes in their migratory capacities,
modification to their lifespan, and secretion of effector cytokines
(e.g. IL-4 and IFN-γ). Most activated naïve T cells become short-
lived effector cells, but some enter the long-lived memory T cell
pool. Memory T cells in humans can be characterized by the
expression of the short isoform of CD45, namely CD45RO.
Memory cells respond more rapidly to antigen challenge and
have a diverse array of effector functions.
During T-cell stimulation, the recognition of the peptide–MHC
complex by a TCR induces clustering of the TCR in concert
with other cell surface receptors. Engagement of the TCR
induces activation of signaling cascades that result in
changes in the transcriptional program of the T cell. Naïve
T cells have stringent requirements for activation and depend
on a second signal, which is generally contributed by
professional APCs in secondary lymphoid organs. The
second signal gives an independent stimulus to the naïve
T cells and is triggered by ligation of nonpolymorphic cell
surface receptors. Extensive work has demonstrated that the
44 kDa glycoprotein CD28 is the major co-stimulatory
molecule involved in T-cell activation [7]. CD28 co-stimulation
increases the expression of lymphokine mRNAs, in particular
those for IL-2 and IL-4 [8–10], and regulates the expression
of Bcl-xL [11], CD152 (cytotoxic T lymphocyte-associated
antigen [CTLA]4) [12], the high-affinity receptor for IL-2
(CD25) [13] and CD154 (CD40 ligand) [14], all of which
contribute to successful progression of T-cell responses. In
contrast to naïve T cells, memory cells do not require co-
stimulation for activation. Thus, memory T cells do not depend
on the interaction with professional APCs for activation,
provided their specific antigen can be presented in the context
of the appropriate MHC molecules by nonprofessional APCs.
CD8+ T cells in rheumatoid inflammation
The natural function of CD8+ T cells is related to protection
against viral infections and tumors. CD8+ T cells perform this
function by inflicting cytotoxic damage to target cells that
express MHC class I molecules and the relevant antigenic
peptide. Because almost all cells express MHC class I
molecules, it is clear that CD8+ cells have a great potential to
cause tissue damage. In addition, activated CD8+ T cells can
produce very high levels of tumor necrosis factor (TNF) and
IFN-γ, which may contribute directly and/or indirectly to target
cell destruction in autoimmune diseases.
Some recent evidence has indicated a role for autoreactive
CD8+ T cells in rheumatoid inflammation. A subgroup of
CD8+ T cells, which co-express CD57, accumulates with
duration of disease in the peripheral blood and the synovial
fluid [15]. Of interest, those CD57+CD8+ T cells exhibit a
remarkable condensation in their TCR repertoire [15–17],
and unrelated RA patients carry clonally dominant CD8+
T cell β receptors with identical amino acid sequences [17].
These findings strongly suggest selection of CD57+CD8+
T cells by a common antigen, although it remains to be shown
whether these CD8+ cells are selected by a self-antigen that
is relevant to the pathogenesis of RA or by an environmental
antigen that is independent of the disease. In this regard,
CD8+ T cells specific for cytomegalovirus, Epstein–Barr
virus, and influenza virus are enriched in the synovial fluid
compared with peripheral blood in RA patients [18], and
clonal or oligoclonal populations of CD8+ T cells dominate
the responses to these viral antigens in synovial fluid from RA
patients. Therefore, T cell clonality at the site of inflammation
may reflect enrichment for memory T cells specific for foreign
antigens rather than proliferation of autoreactive T cells
specific for self-antigen.
Two independent observations indicate a role for CD8+ cells
in disease progression in RA. First, synovial CD8+ T cells
contain significant frequencies of IFN-γ producing effector
cells that might contribute to sustained inflammation by
secreting proinflammatory cytokines [19]. Second, CD8+
T cells may regulate the structural integrity and functional
activity of germinal center-like structures in ectopic lymphoid
follicles within the synovial membrane [20,21]. Taken
together, the data suggest that activated CD8+ T cells are
involved in aggravating pathologic responses in rheumatoid
synovitis. Interestingly, however, studies in animals deficient
for CD4 or CD8 have clearly demonstrated limited impor-
tance of CD8+ T cells in initiating and maintaining auto-
immune inflammatory arthritis. Whereas B10.Q mice lacking
CD4 are less susceptible to collagen-induced arthritis (CIA),
but not completely resistant, the CD8 deficiency has no
significant impact on the disease [22]. Moreover, in mice
transgenic for the RA susceptibility gene HLA-DQ8, CD4-
deficient mice were resistant to development of CIA whereas
CD8-deficient mice developed disease with increased
incidence and greater severity [23]. These data indicate that
CD8+ T cells are not only incapable of initiating CIA but may,
alternatively, have a regulatory/protective effect on auto-
immune inflammation. The precise role played by CD8+ T cells
as effectors and regulators of rheumatoid inflammation
remains to be clarified.
CD4+ T cells in rheumatoid inflammation
It has become clear in recent years that the mechanisms
resulting in the destruction of tissue and the loss of organ
function during the course of an autoimmune disease are
essentially the same as in protective immunity against invasive
micro-organisms. Of fundamental importance in initiating,S7
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controlling, and driving these specific immune responses are
activated CD4+ T cells. Once activated, CD4+ T cells
differentiate into specialized effector cells and become the
central regulators of specific immune responses. In RA a
number of observations are consistent with the hypothesis
that CD4+ T cells play a dominant role in the immuno-
pathogenesis of the disease (Table 1). For example, activated
CD4+ T cells can be found in the inflammatory infiltrates of
the rheumatoid synovium [24]. CD4+ T cells play an
important role in a variety of animal models of inflammatory
arthritis, and tissue-damaging autoimmunity can be induced
by transfer of CD4+ T cells from sick animals into healthy
syngeneic recipients [25,26]. Moreover, appropriate T-cell
directed therapies have clearly conferred clinical benefit in
RA (Table 2) [27–29]. However, the most compelling finding,
implying a central role for CD4+ T cells in propagating
rheumatoid inflammation, remains the association of
aggressive forms of the disease with particular MHC class II
alleles, such as subtypes of HLA-DR4, that contain similar
amino acid motifs in the CDR3 region of the DRβ chain [30,31].
Although the exact meaning of this association has not been
resolved, all interpretations imply that CD4+ T cells orchestrate
the local inflammation and cellular infiltration, after which a large
number of subsequent inflammatory events occur.
Whereas the specific antigen(s) recognized by the
autoreactive CD4+ T cells is still unknown in RA, much
progress has been made in defining the phenotype and
function of those pathogenic CD4+ T cells. In 1986 it was
discovered that repeated antigen-specific stimulation of
murine CD4+ T cells in vitro results in the development of
restricted and stereotyped patterns of cytokine secretion
profiles in the resultant T-cell populations [32]. Based on
these distinctive cytokine secretion patterns and concomitant
effector functions, CD4+ T cells can be divided into at least
two major subsets (Fig. 2). Th1 cells develop preferentially
during infections with intracellular bacteria. Upon activation,
Th1 cells secrete the proinflammatory cytokines IL-2, IFN-γ
and lymphotoxin-α (LT, TNF-β). They activate macrophages to
produce reactive oxygen intermediates and nitric oxide,
stimulate their phagocytic functions, and enhance their ability
for antigen presentation by upregulating MHC class II
molecules. Moreover, Th1 cells promote the induction of
complement fixing, opsonizing antibodies and of antibodies
involved in antibody-dependent cell cytotoxicity (e.g. IgG1 in
humans and IgG2a in mice). Consequently, Th1 cells are
involved in cell-mediated immunity. Immune responses driven
by Th1 cells are exemplified by the delayed-type
hypersensitivity reaction [32,33]. Th2 cells predominate after
infestations with gastrointestinal nematodes and helminths.
They produce the anti-inflammatory cytokines IL-4 and IL-5,
and provide potent help for B-cell activation and Ig class
switching to IgE and subtypes of IgG that do not fix
complement (e.g. IgG2 in humans and IgG1 in the mouse).
Th2 cells mediate allergic immune responses and have been
associated with downmodulation of macrophage activation,
which is conferred largely by the anti-inflammatory effects of
IL-4 [32,33].
The different functional T-cell subsets do not derive from
different pre-committed lineages but rather develop from the
same uncommitted precursor cell under the influence of
environmental and genetic factors [34]. Differentiation of the
appropriate T-cell subset is of crucial importance to the host
in mounting protective immunity against exogenous micro-
organisms. However, it is apparent that immune responses
driven preferentially by activated T-cell subsets are also
involved in the development of pathologic immune disorders.
Whereas atopic diseases result from Th2-dominated
Table 1
Indications for a pathogenic role for CD4+ T cells in
rheumatoid inflammation
Association of rheumatoid arthritis with HLA-DR4 and HLA-DR1 
subtypes (shared epitope)
Enrichment of activated CD4+ memory T cells in peripheral blood, 
synovial membrane, and synovial fluid
Important role in disease initiation in several animal models of 
inflammatory arthritis
Clinical efficacy of appropriate T-cell directed therapies
Table 2
T cell directed therapies in rheumatoid arthritis
Intervention Examples
Reduction in T cell number or function Total lymphoid irradiation
Thoracic duct drainage
Immunosuppressive drugs Glucocorticoids
Methotrexate
Leflunomide
Cyclosporine
FK 506 (tacrolimus)
Rapamycin (sirolimus)
Biologicals TCR vaccination
mAbs to T cell surface 
receptors
mAbs to surface receptors 
on cells interacting with 
T cells
Cytokines, mAbs to 
cytokines
Inhibitors of T cell/APC 
interactions
APC, antigen-presenting cell; mAb, monoclonal antibody; TCR, T-cell
receptor.S8
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responses to environmental allergens, Th1-mediated immunity
is involved in the generation of several organ-specific
experimental autoimmune diseases in animals, such as
experimental allergic encephalomyelitis, insulin-dependent
diabetes mellitus, and CIA [33]. Although dichotomizing
complex diseases such as RA in terms of Th1 or Th2 patterns
may be an over-simplification, evidence is accumulating that
suggests that human autoimmune diseases, such as RA,
might also be driven by preferentially activated Th1 cells
without sufficient Th2 cell development to downregulate
inflammation.
Rheumatoid inflammation is characterized by
a dominant pathogenic Th1 drive
Various epidemiologic and clinical observations suggest a
pathogenic Th1 drive in rheumatoid inflammation. For several
decades, clinical observations have highlighted the
ameliorating effect of pregnancy on the course of RA [35].
Pregnancy improves the symptoms of RA in about 75% of
women, leading to significant resolution of inflammation and
relief from symptoms, which enables the patients to taper or
even stop the use of medications. In fact, the effect of
pregnancy on RA activity is greater than the effect of some of
the newer therapeutic agents. Although the mechanisms
underlying this phenomenon remain unclear, a marked
decrease in Th1-mediated immunity during pregnancy has
been firmly established. For example, pregnant women have a
higher incidence of infections than do nonpregnant females,
in particular infections with intracellular pathogens. The
characteristic Th1 immune reaction, delayed-type hyper-
sensitivity, is diminished during pregnancy. Most recently, a
placental derived protein (placental protein 14) could be
identified that inhibited Th1 immune responses and
synergized with IL-4 to promote Th2 immunity by inhibiting
the downmodulation of the Th2 specific transcription factor
GATA-3 [36]. Together, the data suggest that pregnancy
induces a shift from Th1 to Th2 immune responses, thereby
increasing anti-inflammatory cytokines, which may contribute
to the gestational amelioration of RA. Interestingly, relapses
of RA occur within 6 months postpartum in 90% of cases. At
that time, pregnancy-associated alterations in Th subset
activation can no longer be found [35], suggesting that the
beneficial Th2 shift has resolved and has allowed the Th1-
dominated autoimmune inflammation to recur.
Patients with RA have a decreased prevalence of allergic
diseases [37]. Moreover, those patients with RA who, for
example, have hay fever have less severe disease than do
control patients with RA without hay fever [37]. As expected,
atopic RA patients have higher levels of serum IgE and
peripheral blood eosinophils, but their T cells produce less
IFN-γ after maximum in vitro stimulation [37]. Because allergy
is the prototype Th2 disease and activated Th2 cells are able
to inhibit the generation and the function of Th1 effectors,
these studies support the contention that the occurrence of a
Th2-mediated immune response might be beneficial in RA by
inhibiting Th1 driven immunity.
Exogenous cytokines have been used increasingly in recent
years in an attempt to modulate the immune system and to
initiate antitumor or antiviral cellular immune responses.
These therapies, some of which are still experimental, provide
opportunities to explore the effect of cytokines on T-cell
function and differentiation after in vivo application and their
effect on autoimmunity. IFN-α is a potent inducer of Th1
differentiation, and thus of cellular immunity in humans, and
has been used in chronic viral infections and in attempts to
promote antitumor immunity. However, the incidence of
autoimmune diseases associated with IFN-α treatment
ranges between 4% and 19%, and several authors have
noted the first onset of RA or an exacerbation of pre-existing
disease [38]. Like IFN-α, IL-12 is a strong inducer of Th1 cell
development in humans. In an attempt to enhance antitumor
cellular cytotoxicity, IL-12 has been employed in an
Figure 2
Differentiation of CD4 T cells into specialized Th1 or Th2 effector cells. Upon activation with specific antigen, CD4 T cells proliferate and
differentiate into either the Th1 or the Th2 subset. Th1 cells promote cellular immunity and are involved in the development of autoimmune
diseases; Th2 cells mediate humoral immunity and are involved in allergic immune responses. IFN, interferon; IL, interleukin; Th, T-helper (cell).S9
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experimental treatment for different forms of cancer. When
IL-12 was given to a woman with metastatic cervical cancer,
a severe exacerbation in her RA was noted [39]. Together,
these in vivo effects of cytokines that induce Th1 immune
responses strongly emphasize the role played by
differentiated Th1 effectors in the pathogenesis of RA.
Apart from these clinical observations, various experimental
approaches have also emphasized the dominance of activated
Th1 effector cells in rheumatoid inflammation. For example, the
vast majority of T cell clones from the human rheumatoid
synovial membrane functionally represent the Th1 subset,
producing large amounts of IFN-γ but no IL-4 upon challenge
with their specific antigens [40,41]. In the majority of synovial
biopsies, IFN-γ – as assessed by different techniques –
prevails, whereas IL-4 is rarely found [42,43]. Importantly,
synovial fluid and synovial tissue derived T cells express
activation markers on their surface, indicating that these IFN-γ
expressing cells are actively engaged in driving synovial
inflammation. The frequency of IFN-γ producing CD4+ T cells
is significantly increased in the synovial fluid as compared with
the peripheral blood [44], resulting in a markedly elevated
Th1/Th2 ratio in the synovial fluid that correlates with disease
activity [45]. Likewise, drastically reduced synthesis of IL-4
and IL-10 mRNA by synovial fluid mononuclear cells from RA
patients correlates with disease activity [46]. Finally, when
synovial fluid T cells were cultured in the presence of IL-4, they
were remarkably stable and resistant to Th2 inducing priming
conditions [44]. Together, these data strongly suggest that
CD4+ T cells from the inflamed rheumatoid synovium
represent activated Th1 cells, secreting IFN-γ, which, in turn,
orchestrates synovial inflammation.
Activated CD4+ T cells expressing elevated mRNA levels for
IL-2 and/or for IFN-γ can also be detected in the peripheral
blood of patients with active RA [47]. Most interestingly,
when re-entry of circulating T cells into sites of inflammation
in vivo was blocked by administration of a mAb to intercellular
adhesion molecule (ICAM)-1 (CD54), a significant increase in
IFN-γ mRNA levels in the peripheral blood occurred that
might reflect a redistribution of activated Th1 cells from sites
of inflammation into the peripheral circulation [47]. Moreover,
the frequencies of IFN-γ secreting peripheral blood T cells in
patients with new onset synovitis (duration <1 year) correlate
well with disease activity, emphasizing the role of Th1 cells in
the initiation of the disease [48].
Together, the data strongly imply that Th1 cells and their
cytokines are not only present in RA but significantly
contribute to the perpetuation of chronic inflammation.
CD4+ T cells as regulators of autoimmune
inflammation
In recent years it has become apparent that CD4+ T cells do
not only propagate specific immune responses as effector
cells; subsets of CD4+ T cells have also been identified that
are able to inhibit the initiation of immune reactions and even
downregulate established immune responses. These CD4+ T
cells are termed regulatory T cells and have, because of their
role in the immunopathogenesis of autoimmune diseases and
their potential use in therapeutic applications, become the
focus of intensive research. Several T cells with regulatory
capacity have been described. Tr1 cells have immune
regulatory activities both in vitro and  in vivo and produce
large amounts of IL-10 [49,50]. The small subset of Th3 cells
predominantly secretes the immunomodulatory cytokine
transforming growth factor-β and develops in vivo after
immunization through an oral or other mucosal route [51].
Th3 cells have been detected in patients with multiple
sclerosis after oral administration of myelin basic protein [52].
Like Tr1 cells, Th3 cells can downregulate Th1 inflammation,
and it is speculated that both subsets play a role in
maintaining peripheral tolerance [53]. However, the precise
function of those cells in immune homeostasis and, moreover,
in autoimmune inflammation has not been conclusively
addressed.
One particularly interesting CD4+ T-cell subset with
regulatory capacity is defined by the constitutive expression
of the α chain of the IL-2 receptor, CD25. CD25+ regulatory
CD4+ T cells (Treg cells) were isolated first in mice, in which
it was shown that transfer of CD4+ T cells that were depleted
of the CD25-expressing T-cell fraction into athymic syngeneic
Balb/c mice resulted in the development of various organ-
specific autoimmune diseases, such as thyroiditis, gastritis,
colitis, and insulin-dependent autoimmune diabetes [54].
Furthermore, co-transfer of CD4+CD25+ T cells with the
pathogenic CD4+CD25– T cells prevented the development
of experimentally induced autoimmune diseases [55,56].
These data imply that CD25+ Treg cells are able to regulate
actively the responsiveness of autoreactive T cells that have
escaped central tolerance. Subsequently, Treg cells were
also detected in humans [57–63]. Treg cells are part of the
physiologic peripheral T-cell repertoire and constitute
between 5% and 15% of CD4+ T cells in the peripheral
blood of healthy individuals. Treg cells are anergic (i.e. they
do not proliferate in response to mitogenic stimulation) [64].
Of importance, CD25+CD4+ T cells, in contrast to their
CD25– counterparts, are able to inhibit activation-induced
proliferation of autologous responder T cells in a contact-
dependent and cytokine-independent manner [58]. Both
anergy and inhibition of proliferation can be prevented by the
addition of exogenous IL-2 [65]. Apart from their constitutive
expression of CD25, Treg cells are characterized pheno-
typically by surface expression of CTLA4 [66] and
glucocorticoid induced TNF receptor family related protein
[67], as well as by the expression of the transcription factor
Foxp3 [68]. The importance of Foxp3 for the regulatory
function of Treg cells has been demonstrated by transfection
of CD25–CD4+ T cells with a plasmid encoding Foxp3, which
conferred a regulatory capacity to the transfected T cells
[68]. A comprehensive review on the function of Treg cells inS10
immune homeostasis is beyond the scope of this article;
excellent summaries have been published elsewhere [68,69].
Together, the accumulated evidence indicates that Treg cells
may play an important role in maintaining peripheral tolerance
and preventing the evolution of autoimmune inflammation.
In a series of recent reports, Treg cells were identified and
analyzed in different rheumatic diseases, but their role is
incompletely understood. Whereas controversy exists with
regard to the frequency of Treg cells in the peripheral
circulation of patients with rheumatoid inflammation [49,52,70],
it appears clear that elevated numbers of Treg cells are present
in the inflamed synovial tissue of patients with RA as compared
with the peripheral circulation [50,70]. When examined in
conventional  in vitro assays, synovial Treg cells are able to
suppress the proliferation of autologous CD4+CD25–
responder T cells of synovial and peripheral origin [50,52,70].
Of interest, synovial Treg cells exhibit an increased suppressive
capacity as compared with blood Treg cells in RA [70].
Several mechanisms may contribute to the apparent paradox
of local inflammation despite increased frequencies of Treg
cells with enhanced suppressor activity in vitro. First, as
synovial Treg cells exhibit functional differences before and
after anti-TNF-treatment, it has been suggested that TNF
inhibits Treg cells and prevents their regulatory function in vivo
[49]. Similarly, other constituents of the synovial environment,
such as IL-2, and other mediators of inflammation, such as IL-
7, or APCs that are able to engage co-stimulatory ligands on
the synovial Treg cells, abrogate the function of Treg cells
[65,71]. Second, synovial responder T cells express
decreased susceptibility to the regulatory effect of Treg cells
as compared with peripheral blood responder T cells, thereby
‘compensating’ for the enhanced regulatory capacity of the
synovial Treg cells [70]. Finally, although suppression by Treg
cells is probably not antigen specific but may involve
neighboring T cells in a ‘bystander’ manner [51], Treg cells
require activation through their TCR to deliver their regulatory
function. Thus, if the specific antigen for the synovial Treg cells
is not presented either in the secondary lymphoid organs or in
the inflamed synovia, or, alternatively, if Treg cells in RA
express an altered threshold for antigen-specific activation,
then synovial Treg cells, albeit present, will not become
activated and therefore will fail to inhibit ongoing inflammation.
A final important CD4+ T-cell subset with regulatory capacity
for Th1 inflammation is the Th2 subset that antagonizes the
generation of Th1 cells and their effector functions largely via
its signature cytokine IL-4. For instance, the generation of Th1
cells can be effectively blocked by high concentrations of IL-4,
even in the presence of IL-12 [72]. At the level of effector
functions, IL-4 antagonizes much of the proinflammatory effect
of IFN-γ and inhibits the proliferation of Th1 cells.
Consequently, IL-4 has been used in vivo as a treatment for
experimental autoimmune diseases in animals and in patients
with psoriasis [73]. In animal models, IL-4 is the most
successful means by which to ameliorate autoimmune
disorders that are caused by activated Th1 cells. For example,
IL-4 improves experimental allergic encephalomyelitis, delays
the onset and diminishes clinical symptoms of CIA, and
prevents joint damage and bone erosion in this experimental
autoimmune disease [74]. In vitro, IL-4 suppresses
metalloproteinase production and stimulates production of
tissue inhibitor of metalloproteinases-1 in human mononuclear
phagocytes and cartilage explants, indicating a protective
effect of IL-4 toward extracellular matrix degradation.
Furthermore, IL-4 inhibits bone resorption through an effect on
both osteoclast activity and survival [75] and reduces the
spontaneous secretion of proinflammatory cytokines and Ig in
ex vivo cultured pieces from the rheumatoid synovial
membrane [76]. Finally, IL-4 downregulates the surface
expression of CD5 on B cells and inhibits spontaneous Ig and
IgM rheumatoid factor production in patients with RA [77].
Together, the Th2 cytokine IL-4 has potent immunomodulatory
functions that affect different cellular targets and is capable of
ameliorating signs and symptoms of chronic arthritis.
As discussed above, rheumatoid inflammation is
characterized by the predominance of IFN-γ and the absence
of IL-4. However, these data do not yet permit a conclusion to
be drawn regarding whether Th1 cells are the initiators of
rheumatoid inflammation or rather appear as a consequence
of it. In other words, the observations described above do not
identify the mechanisms underlying the dominant pathogenic
Th1 drive in RA. In order to address this issue, studies were
carried out to assess the functional capability of T cells in RA
patients with regard to their plasticity to differentiate into Th1
and Th2 effector cells. In these studies, it became obvious
that isolated memory CD4+ T cells from the majority of
patients with very early treatment-naïve RA (disease duration
<6 months and no previous treatment with disease modifying
antirheumatic drugs [DMARDs] or corticosteroids) manifest a
profound inability to mount Th2 responses [78]. Thus, at the
onset of the disease, those patients cannot generate
immunoregulatory Th2 cells that might downregulate ongoing
Th1-mediated inflammation. Failure to downregulate activated
Th1 cells at disease initiation might thereby allow Th1
inflammation to persist and evolve into chronic inflammation,
characterized by the continuous activation of T cells, macro-
phages, fibroblasts, and osteoclasts and, subsequently, the
destruction of tissue. Because this functional abnormality of
CD4+ T cells in RA is evident at the time of initial clinical
symptoms of arthritis [78], the data strongly suggest that the
failure of CD4+ T cells in RA to generate Th2 effectors is the
basis that allows Th1 dominated chronic immunity to develop,
and is not merely its consequence.
T-cell directed therapies
Based on the concept that activated T cells are the key
mediators of chronic autoimmune inflammation, various T-cell
directed therapeutic interventions have been introduced for
the treatment of RA. Comprehensive reviews have discussed
Arthritis Research & Therapy    March 2005 Vol 7 Suppl 2 Skapenko et al.S11
the concepts and the clinical efficacy of T-cell directed
therapy in RA [79–82]. Here, we review those approaches
that target the pathogenetically important alterations in CD4+
T cell functions as outlined above.
Because RA is driven by proinflammatory Th1 cells with
impaired differentiation of immunoregulatory Th2 cells, a shift
in the balance of Th1/Th2 effector cells toward anti-
inflammatory Th2 cells would be expected to be clinically
beneficial. The concept of modulating the Th1/Th2 balance
as a treatment for chronic autoimmunity has been successfully
applied in a number of animal models of autoimmune
diseases [83,84]. It is therefore of interest that several recent
studies have indicated that DMARDs appear to be able to
modulate the Th1/Th2 balance. For example, leflunomide, a
potent nontoxic inhibitor of the rate-limiting enzyme of the de
novo synthesis of pyrimidines, dihydro-orotate dehydrogenase
[85], selectively decreases the activation of proinflammatory
Th1 cells while promoting Th2 cell differentiation from naïve
precursors [86]. Sulfasalazine potently inhibits the production
of IL-12 in a dose-dependent manner in mouse macrophages
stimulated with lipopolysaccharide. Importantly, pretreatment
of macrophages with sulfasalazine either in vitro or in vivo
reduces their ability to induce the Th1 cytokine IFN-γ and
increases the ability to induce the Th2 cytokine IL-4 in
antigen-primed CD4+ T cells [87]. Methotrexate significantly
decreases the production of IFN-γ and IL-2 by in vitro
stimulated peripheral blood mononuclear cells while
increasing the concentration of IL-4 and IL-10 [88]. Likewise,
clinical efficacy of cyclosporine is associated with decreased
serum levels of IFN-γ, IL-2 and IL-12, and with significant
increases in IL-10 [89]. Bucillamine decreases the frequency
of IFN-γ producing CD4+ T cells generated after a priming
culture of mononuclear cells from the peripheral blood [90].
Finally, reports have suggested that glucocorticoids inhibit
cytokine expression indirectly through promotion of a Th2
cytokine secretion profile, presumably by their action on
monocyte activation [91]. Together, the data suggest that the
anti-inflammatory effect of a number of current treatment
modalities in RA is characterized by an inhibition of Th1 cell
activation and effector cell generation, and by favoring Th2
differentiation, thereby shifting the Th1/Th2 balance toward Th2.
In an attempt to target only those cells that perpetuate the
chronic inflammation specifically, with minimal effects on
other aspects of the immune or inflammatory systems,
therapeutic tools (‘biologicals’) with defined targets and
effector functions have been designed and tested in clinical
applications. Because CD4+ T cells are central in initiating
and perpetuating the chronic autoimmune response in
rheumatic diseases, many biologicals are aimed at interfering
with T-cell activation and/or migration.
A major advance in our understanding of T-cell activation has
been the identification of the critical co-stimulatory molecules
on T cells, such as CD28, lymphocyte function-associated
antigen (LFA)-1, CD2, CD4, CD30, CD44, and CD154
(CD40L), and their interacting ligands on APCs or B cells.
Although these molecules act through different mechanisms,
some delivering co-stimulatory biochemical signals to the T
cell and some enhancing adhesion to target tissues, they all
have the ability to augment the T-cell proliferative responses
to antigenic stimuli. Biologicals designed to interfere with co-
stimulation via inhibiting engagement of co-stimulatory
ligands have been used in several animal models of
inflammatory arthritis and in treatment trials in RA. In
experimental autoimmune diseases in animals, mAbs to CD4
have been used to prevent the induction of the disease
[92,93]. Of relevance to human disease, mAbs to CD4 were
also able to inhibit further progression when given after the
initial inflammation had already become manifest [93,94],
although, with one notable exception [95], controlled human
trials have largely failed to demonstrate favorable results to
date [79]. Interaction of CD2 with its ligand, CD58 has been
blocked by application of a soluble fully human recombinant
fusion protein comprising the first extracellular domain of CD58
and the hinge, CH2 and CH3 sequences of human IgG1
(LFA-3–IgG1; alefacept). Alefacept has been employed in
patients with psoriasis, with substantial clinical response [96].
Inhibition of CD28-mediated co-stimulatory signals is a
potent means of immunosuppression that can be achieved by
blocking either CD28 or CD80 and CD86. Currently,
humanized anti-B7 mAbs are in phase II clinical trials for solid
organ transplantation, graft versus host disease, and mild to
severe plaque psoriasis. An alternative approach to block
CD28 co-stimulation is by coating CD80 and CD86 with a
soluble Ig fusion protein of the extracellular domain of CTLA4
(CD152). CTLA4 is a homolog to CD28 and is expressed by
activated T cells. It can bind both CD80 and CD86 with
higher affinity than CD28. Because CD152 has a high affinity
for CD80 and CD86, soluble forms of CTLA4 inhibit the
interaction of CD28 with its ligands. In clinical trials,
CTLA4–Ig (CTLA4–IgG1; abatacept) had favorable effects in
patients with psoriasis vulgaris [97] and in patients with RA
[98,99].
The adhesion receptor/counter-receptor pair, LFA-1 (CD11α/
CD18) and ICAM-1, is critical for transendothelial migration
of T cells and their subsequent activation [100]. Therefore,
mAbs to LFA-1 and ICAM-1 have been employed in auto-
immune diseases in an attempt to block migration of T cells
into sites of inflammation and their subsequent stimulation by
locally expressed antigenic peptides in vivo [47,101].
Significant clinical benefit was achieved with a mAb to
ICAM-1 in patients with active RA [101]. It is of interest that
clinical benefit was restricted to those patients who showed a
marked increase in the levels of Th1 cytokine producing
T cells in their circulation immediately after administration of
the mAb [47]. Thus, it can be reasoned that, in responding
patients, the circulatory pattern of activated Th1 cells was
altered by inhibiting their migration into the inflamed
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synovium. These data emphasize the pathogenic Th1 drive in
those patients who respond to therapy.
Together, T-cell directed therapy in RA is based on the
concept that CD4+ T cells initiate and continuously drive
systemic rheumatoid inflammation. T-cell directed DMARDs
and some of the recently employed mAbs have been
successful in ameliorating signs and symptoms of the diseases,
and some also seem able to slow disease progression. Thus,
although sustained clinical improvement has not been achieved
with a short course of biologicals, the idea that targeting CD4+
T cells as the controllers of rheumatoid inflammation will
interrupt chronic autoimmune inflammation and subsequent
tissue destruction has received strong support.
Conclusion
Together, strong evidence indicates a critical role for CD4+
T cells in the pathogenesis of rheumatoid inflammation.
However, their role appears to exceed that of activated
proinflammatory Th1 effector cells, which promote many
aspects of synovial inflammation. Rather, it has become
apparent that, in RA, CD4+ T cell subsets with regulatory
capacity, such as Th2 cells and CD25+ Treg cells, are
functionally impaired, thus allowing Th1 driven immunity to
evolve and progress into chronic inflammation. Interference
with the activation and generation of Th1 cells and with the
activity of their secreted cytokines might therefore be
beneficial in the treatment of RA. Those therapies might
include biologicals that target CD4+ effector T cells but also
novel approaches that induce and/or enhance the function of
regulatory T cells in vivo.
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